OOIR: Observatory of International Research

Papers

(The TQCC of JACC: Cardiooncology is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Full Issue PDF	194
Priorities in Cardio-Oncology	176
Atrial Fibrillation in Patients With Cancer	133
Full Issue PDF	116
To Anticoagulate or Not to Anticoagulate to Prevent Arterial Thrombosis During Systemic Cancer Therapy	105
Full Issue PDF	104
Epigenomics of Cardio-Oncology	101
LAG3 Blockade Expands T Cells Within Atherosclerotic Plaque	87
Hormonal Therapy and Cardiovascular Health	77
Behaviorally Designed Gamification and Physical Activity Among Breast and Prostate Cancer Survivors	76
Balancing Promise and Evidence	75
Deep Inspiration Breath Hold in Left-Sided Breast Radiotherapy	74
Cardiovascular Safety in Oncology Clinical Trials	69
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes	66
Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients	63
Cancer Therapy and Exercise Intolerance: The Heart Is But a Part	62
Moving the Pendulum for Earlier Detection of Systolic and Diastolic Dysfunction in Cancer Survivors	60
Full Issue PDF	57
Assessing Neurohormonal Antagonist Withdrawal in HER2+ Breast Cancer Patients With CTRCD	55
Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy	54
Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients	52
Cardiac Risk Stratification Before Lung Cancer Radiation	51
Frailty	49
Long-Term, Implantable Event Monitoring of Patients With Wild-Type Transthyretin Cardiac Amyloidosis	46
Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy	45

Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma	45
Risk Prediction in Cardio-Oncology: Conceptual and Methodological Considerations	42
Incretin Mimetics in Cancer and Cardiovascular Disease	41
Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms	41
Proactive Surveillance for ICI Cardiotoxicity	41
Atorvastatin Does Not Attenuate Aortic Stiffening After Doxorubicin for Breast Cancer and Lymphoma (PREVENT-WF-98213)	41
Editorial Board/Officers Page	40
Atrial Fibrillation After Stem Cell Transplantation	39
Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD	39
Cancer Immunotherapy Beyond Checkpoint Blockade	39
Full Issue PDF	39
Peripheral Ischemia Fuels Breast Cancer Via Myeloid-Skewed Hematopoiesis	39
Changes in Physical Activity and Cardiovascular Disease Risk in Cancer Survivors	38
Clonal Hematopoiesis in Cancer and Cardiovascular Disease	37
Correlation of Natriuretic Peptides with Invasively Measured Intracardiac Filling Pressures in Patients With Cancer	36
Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients	36
Permissive Cardiotoxicity	35
Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance	35
Full Issue PDF	34
The Association of Malignancy With Stroke and Bleeding in Atrial Fibrillation	33
Leveling Up	32
Developing a Model for Cross-Institutional Educational Collaborations	31
Endothelin-1	30
Editorial Board	30
Coronary Artery Calcium Scores After Prophylactic Premenopausal Bilateral Salpingo-Oophorectomy	29
Reply	29
Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity	28
Outcomes of Patients With Myeloproliferative Neoplasms Admitted With Myocardial Infarction	28
Correction	27
Differential Transthyretin Stabilization in Patients With Wild Type and Variant Transthyretin Amyloidosis	27
Mismatch Between Preclinical Cardio-Oncology and Clinical Oncology Research	27
Artificial Intelligence to Complement, Not Replace, Clinical Knowledge	26
Quality-of-Care Measures for Cardio-Oncology	26
Dantrolene as a Potential Strategy to Prevent Doxorubicin-Induced Cardiotoxicity	26
Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity	26
High-Sensitivity Troponin I	25
Fluoropyrimidine Therapy in Gastrointestinal Cancer	25
Reply	24
Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction	24
Genetic Testing in Evaluating Risk of Anthracycline Cardiomyopathy	24
Enalapril for Preventing Cardiotoxicity After High-Dose Anthracycline Therapy in Breast Cancer and Lymphoma Patients	24
Full Issue PDF	24
Deep Inspiration Breath Hold to Reduce Cardiovascular Disease Risk for Breast Radiotherapy	23
CHA2DS2-VASc Score in Cardio-Oncology	23
Prognosis of MPN Patients Experiencing Acute Thrombotic Events and the Potential Role of Cytoreduction	23
Baseline Cardiac Parameters as Biomarkers of Radiation Cardiotoxicity in Lung Cancer	23
Vascular Complications of Atrial Fibrillation in Patients With Cancer	23
Heart Failure Readmission in Patients With ST-Segment Elevation Myocardial Infarction and Active Cancer	22
Endoplasmic Reticulum Selective Autophagy Alleviates Anthracycline-Induced Cardiotoxicity	22
Reframing Mechanistic and Clinical Paradigms of Osimertinib-Associated Cardiotoxicity	22

Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia	21
Racial and Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Cancer Patients in the U.S.	21
Low QRS Voltages in Cardiac Amyloidosis	21
Diet and Prevention of Cardiovascular Disease and Cancer	21
Imaging Immune Checkpoint Inhibitor Myocarditis	21
The United Kingdom’s First Cardio-Oncology Service	21
Association of Midlife Cardiovascular Health and Subsequent Change in Cardiovascular Health With Incident Cancer	20
To Adjudicate or Not Adjudicate	20
Full Issue PDF	20
Cancer Therapy–Related Cardiac Dysfunction	20
A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?	20
FULL ISSUE PDF	20
Cardiovascular Risk Assessment in Patients With Kidney Cancer	19
Harnessing iPSCs to Dissect Causality in Anthracycline-Induced Cardiotoxicity	19
Second Malignancies and Cardiovascular Disease in Childhood Cancer Survivors	19
Cardiogenic Shock From Chronic Immune Checkpoint Inhibitor Associated Myocarditis Causing Predominant Right Ventricular Failure	19
Redefining Gamification for Cardiovascular Prevention in High-Risk Cancer Survivors	18
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors	18
REPLY	18
Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness	18
What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?	18
Incident Myocardial Infarction, Heart Failure, and Oncologic Outcomes in Breast Cancer Survivors	18
Cardiovascular Care After Cancer	17
Cardiovascular Considerations After Cancer Therapy	17
Navigating the Uncharted	17
A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy	17
Guiding Treatment With Recovered CTRCD	17
(Less) Time and Energy	16
Reply	16
Evaluating Anticoagulant Strategies for Atrial Fibrillation in Patients With Cancer	15
Preventing Cancer Therapy–Related Cardiotoxicity	15
Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer	14
The Cause of Death in Patients With Cancer	14
Clinical Practice Guidelines in Cardio-Oncology	14
Reply	14
The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity	14
Editorial Board	14
Reply	14
Reassessing Troponin Surveillance in Immunotherapy	14
Treatment and Outcomes in Myocardial Infarction and Cancer—A German Real-Life Analysis	14
Addressing the Overlooked	14
Editorial Board/Officers Page	13
Genetic Susceptibility for Anthracycline-Induced Cardiomyopathy	13
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology	13
Full Issue PDF	13
Reply	13
Overcoming LGBTQI+ Disparities in Cardio-Oncology	13
Considerations of Competing Risks Analysis in Cardio-Oncology Studies	13
High-Sensitivity Cardiac Troponin I for Long-Term Cardiovascular Risk Stratification in a Cancer Clinic Population	13
When Clot Is Tumor	13
Postural Orthostatic Tachycardia Syndrome and Orthostatic Hypotension Following Hematopoietic Stem Cell Transplantation	13
A Biomarker-Based Diagnostic Model for Cardiac Dysfunction in Childhood Cancer Survivors	12
The ESC Cardio-Oncology Guidelines	12
Genomics for Improving Heart Failure Risk Assessment in Cancer Patients	12
Reply	12
Predicting Left Ventricular Dysfunction in Childhood Cancer Survivors	12
Growing, Building, and Defining the Field of Cardio-Oncology for Our Patients	12
Learning From Trials	12
When “Uptake” Is Organelle Biology	12
Editorial Board	12
The Association of Metformin With Heart Failure in Patients With Diabetes Mellitus Receiving Anthracycline Chemotherapy	12
Assessing STEMI Outcomes in Patients With Cancer	12
Cancer Diagnosis, Physical Activity, and Heart Disease Risk	12
Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients	12
Full Issue PDF	12
Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy	12
Reply	12
ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity	12